Version June 2024
Azole-resistant C. albicans infection is suspected when the patient's symptoms and physical examination findings are refractory despite appropriately dosed and used azole drugs (any azole). These patients undergo drug resistance testing with assessment of MIC of various antifungal drugs.
This management plan is based on the limited available data and our clinical experience.VVC: vulvovaginal candidiasis; BV: bacterial vaginosis; MIC: minimum inhibitory concentration.
* Discussion of testing options to confirm VVC and/or other causes of symptoms are presented in related UpToDate content on abnormal vaginal discharge.
¶ Treatment of persistent or recurrent C. albicans infection is discussed in related content in UpToDate text and algorithms.
Δ Patients with recurrent infection may need treatment for six months, or more. Some fluconazole resistant infections may be sensitive to ketoconazole or itraconazole. For more information on treatment of sporadic versus recurrent vulvovaginal candidiasis, refer to related discussion in UpToDate content.
◊ Boric acid is only to be used vaginally. Oral consumption of boric acid can result in death.
§ Ibrexafungerp is a triterpenoid antifungal (ie, not an azole) but not for use in pregnant or lactating patients. The optimal dose and duration of treatment are not known. Patients with recurrent VVC may require maintenance therapy (ie, repeat regimen every four weeks for six or more months).آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
